Sugi Predict

Sugi Predict / Compounds / SCHEMBL1241032

SCHEMBL1241032

SCHEMBL1241032

COc1ccc(CCO)cc1F

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.50
▸ TSHR P16473 2/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ NFKB1 P19838 1/20 0.50
▸ ATM Q13315 1/20 0.50
▸ LMNA P02545 4/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ APEX1 P27695 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ HTT P42858 3/20 0.48
▸ MITF O75030 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ MAPK1 P28482 2/20 0.47
▸ TAAR1 Q96RJ0 2/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ CYP17A1 P05093 1/20 0.46
▸ GLA P06280 1/20 0.46
▸ DBH P09172 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL584597 0.89 TNKS2 (0.51) KDM4ETSHRCYP1A2CYP3A4NFKB1
SCHEMBL15022767 0.86 TUBB4A (0.48) KDM4ETSHRCYP1A2CYP3A4NFKB1
SCHEMBL1239104 0.85 TAAR1 (0.51) KDM4ETSHRCYP1A2CYP3A4NFKB1
SCHEMBL2382627 0.85 HTT (0.50) KDM4ELMNAHTTMITFALDH1A1
SCHEMBL9921235 0.83 KDM4E (0.52) KDM4ETSHRCYP1A2CYP3A4NFKB1
SCHEMBL988997 0.83 KDM4E (0.72) KDM4ETSHRCYP1A2CYP3A4NFKB1
SCHEMBL29446268 0.82 ATM (0.66) KDM4ECYP1A2CYP3A4ATMKMT2A
SCHEMBL13098004 0.82 ATM (0.66) KDM4ECYP1A2CYP3A4ATMKMT2A
SCHEMBL296593 0.82 ATM (0.66) KDM4ECYP1A2CYP3A4ATMKMT2A
SCHEMBL13098012 0.82 ATM (0.66) KDM4ECYP1A2CYP3A4ATMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10154995-B2 Serine/threonine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2018-12-18 — — US claimed
EP-3089788-B1 SERINE/THREONINE KINASE INHIBITORS GENENTECH INC (US) 2018-10-24 — — EP claimed
EP-3089980-B1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2018-01-31 — — EP claimed
US-20170348310-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2017-12-07 — — US claimed
US-9763942-B2 Serine/threonine kinase inhibitors GENENTECH, INC. (US) 2017-09-19 — — US claimed
US-9670208-B2 Serine/threonine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2017-06-06 — — US claimed
EP-3089980-A1 SERINE/THREONINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2016-11-09 — — EP claimed
US-20160303126-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-10-20 — — US claimed
US-20160304519-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-10-20 — — US claimed
WO-2015103137-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2015-07-09 — — WO claimed
US-20240150349-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2024-05-09 — — US disclosed
EP-3681885-B1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS FORMA THERAPEUTICS INC (US) 2024-02-28 — — EP disclosed
EP-3681885-B1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS FORMA THERAPEUTICS INC (US) 2024-02-28 — — EP disclosed
US-11787803-B2 Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors FORMA THERAPEUTICS, INC. (US) 2023-10-17 — — US disclosed
US-11787803-B2 Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors FORMA THERAPEUTICS, INC. (US) 2023-10-17 — — US disclosed
EP-1904467-A1 UREA GLUCOKINASE ACTIVATORS Novo Nordisk A/S (DK) 2008-04-02 — — EP disclosed
WO-2007006814-A1 UREA GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 — — WO disclosed
US-20060166940-A1 Amino-propanol derivatives NOVARTIS AG (CH) 2006-07-27 — — US disclosed
EP-1539674-A1 AMINO-PROPANOL DERIVATIVES Novartis AG (CH) 2005-06-15 — — EP disclosed
WO-2004024673-A1 AMINO-PROPANOL DERIVATIVES NOVARTIS AG (CH) 2004-03-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160303126-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, TTBK1, MAP3K11 KDM4E 3418/4885TSHR 3842/4885CYP1A2 4700/4885
US-10154995-B2 Serine/threonine kinase inhibitors MAP3K1, TTBK1, MAP3K11 KDM4E 3418/4885TSHR 3842/4885CYP1A2 4700/4885
US-20060166940-A1 Amino-propanol derivatives ADRB1, ADRB3, ADRA1D KDM4E 1747/4885TSHR 902/4885CYP1A2 143/4885
US-20160304519-A1 SERINE/THREONINE KINASE INHIBITORS TTBK1, MAP3K1, TNNI3K KDM4E 3670/4885TSHR 2352/4885CYP1A2 4602/4885
US-20240150349-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS EP300, CREBBP, BRD3 KDM4E 774/4885TSHR 3483/4885CYP1A2 4720/4885
US-20170348310-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, TTBK1, MAP3K11 KDM4E 3418/4885TSHR 3842/4885CYP1A2 4700/4885
US-11787803-B2 Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors EP300, CREBBP, BRD3 KDM4E 774/4885TSHR 3483/4885CYP1A2 4720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.